Solix Technologies has appointed Dr. Ujwala as Director of Technical Product Management to lead its Life Sciences and AI transformation initiatives. The appointment, effective May 27, 2026, positions the company to enhance its product roadmap strategy and business development across regulated industries. Dr. Ujwala will be based in Mumbai and support strategic growth across India and North America.

Dr. Ujwala brings more than 22 years of experience spanning Global Pharmaceutical R&D, Clinical Research Operations, Pharmacovigilance, and Regulatory Writing. Her expertise covers the Pharmaceutical, Medical Device, and Biosimilar sectors. Previously, she spent over a decade scaling Nucleon Research, a Mumbai-based Contract Research Organization (CRO), where she established Good Pharmacovigilance Practice (GVP)-compliant safety systems and GDPR-compliant cloud-based operations.

Strategic Focus on AI and Digital Transformation

At Solix Technologies, Dr. Ujwala will focus on AI-driven digital transformation, regulatory technology platforms, and enterprise data modernization. Her role involves developing next-generation digital solutions for Life Sciences and regulated industries. The company stated that her experience in pharmacovigilance, clinical operations, and technology modernization will add significant value to global customers.

Executive Commentary

Murali Krishnam of Solix Technologies emphasized the importance of the appointment, noting that the Life Sciences industry is undergoing a fundamental transformation driven by AI and data modernization. He highlighted that leaders combining deep domain expertise with operational excellence are critical for navigating this shift.

About the Companies

Solix Technologies, Inc. is a provider of enterprise data, AI, and data fabric solutions, trusted by Fortune 2000 companies. Its Solix Common Data Platform (CDP) supports cloud data management applications. TechNVision Ventures Limited, the listed entity, is an affiliate of Solix Technologies and focuses on creating next-generation enterprise software businesses.

Technvision Ventures Limited returned to profitability in the financial year ended March 31, 2026, reporting a consolidated net profit of ₹11.43 crore compared to a net loss of ₹82.53 crore in the previous year. The turnaround was driven by a significant increase in revenue from operations, which rose to ₹22,780.86 crore for the full year from ₹3,935.01 crore in FY25. The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026.

The standalone financial results for the year ended March 31, 2026, showed a net profit of ₹74.86 crore, a sharp increase from the loss of ₹0.98 crore reported in the previous year. Income from operations for the standalone entity stood at ₹2,481.10 crore for FY26, up from ₹568.59 crore in the prior year. The standalone net profit for the quarter ended March 31, 2026, stood at ₹9.85 crore.

However, at the consolidated level, the quarter ended March 31, 2026, reflected a net loss of ₹42 million against a net loss of ₹8.3 million in the same quarter of the previous year. Consolidated revenue for the quarter stood at ₹671 million, compared to ₹393.5 million in the year-ago period, reflecting continued top-line growth even as the quarter recorded a loss.

Financial Performance Summary

The following table presents the full-year audited financial results for both standalone and consolidated entities:

The following table summarises the consolidated quarterly performance:

Audit and Governance

M/s. Ramu & Ravi, Statutory Auditors of the Company, issued an audit report with an unmodified opinion on both the standalone and consolidated financial results. The auditors confirmed that the results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The consolidated results include figures from subsidiaries such as STI Corporation Inc., USA, Solix Technologies Inc., USA, and Accele Force Pte Ltd-Singapore.

The Board appointed Mr. Srinivas Podichetty, Finance Head, as the Internal Auditor of the Company for the Financial Year 2026-27. The trading window for the company's securities, which was closed effective April 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, will remain closed until 48 hours after the dissemination of the financial results to the stock exchanges.